$CRIS
CURIS INC Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000110820518000017 Filed on November 01, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$2.755M	$2.847M	$2.444M
YoY Change	-15.54%	16.49%	38.94%
Cost Of Revenue	$150.0K	$150.0K	$120.0K
YoY Change	-11.76%	25.0%	-99.34%
Gross Profit	$2.610M	$2.690M	$2.320M
YoY Change	-15.81%	15.95%	-114.22%
Gross Profit Margin	94.74%	94.49%	94.93%
Selling, General & Admin	$3.040M	$4.130M	$3.410M
YoY Change	-8.16%	21.11%	-27.14%
% of Gross Profit	116.48%	153.53%	146.98%
Research & Development	$4.710M	$4.983M	$13.38M
YoY Change	-31.94%	-62.76%	97.35%
% of Gross Profit	180.46%	185.24%	576.81%
Depreciation & Amortization	$40.00K	$40.00K	$70.00K
YoY Change	-33.33%	-42.86%	40.0%
% of Gross Profit	1.53%	1.49%	3.02%
Operating Expenses	$7.750M	$4.983M	$13.38M
YoY Change	-24.17%	-62.76%	97.35%
Operating Profit	-$5.148M	-$6.417M	-$14.47M
YoY Change	-27.77%	-55.66%	-47.93%
Interest Expense	-$790.0K	$972.0K	$1.109M
YoY Change	-12.22%	-12.35%	68.8%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$806.0K	-$986.0K
YoY Change		-18.26%	77.34%
Pretax Income	-$5.940M	-$7.220M	-$15.46M
YoY Change	-26.03%	-53.3%	-45.47%
Income Tax
% Of Pretax Income
Net Earnings	-$5.941M	-$7.223M	-$15.46M
YoY Change	-26.0%	-53.27%	-45.47%
Net Earnings / Revenue	-215.64%	-253.71%	-632.45%
Basic Earnings Per Share
Diluted Earnings Per Share	-$179.3K	-$217.7K	-$527.6K
COMMON SHARES
Basic Shares Outstanding	33.11M shares	33.18M shares	143.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.30M	$30.80M	$69.20M
YoY Change	-59.63%	-55.49%	29.59%
Cash & Equivalents	$23.60M	$25.56M	$49.84M
Short-Term Investments	$600.0K	$5.300M	$19.40M
Other Short-Term Assets	$800.0K	$1.100M	$1.400M
YoY Change	-20.0%	-21.43%	0.0%
Inventory
Prepaid Expenses
Receivables	$2.864M	$2.855M	$2.456M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$27.96M	$34.82M	$73.00M
YoY Change	-56.51%	-52.31%	28.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$267.0K	$312.0K	$384.0K
YoY Change	-27.05%	-18.75%	-5.42%
Goodwill	$8.982M	$8.982M	$8.982M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.000K	$3.000K	$3.000K
YoY Change	-33.33%	0.0%	0.0%
Total Long-Term Assets	$9.404M	$9.450M	$9.369M
YoY Change	-1.05%	0.86%	-1.83%
TOTAL ASSETS
Total Short-Term Assets	$27.96M	$34.82M	$73.00M
Total Long-Term Assets	$9.404M	$9.450M	$9.369M
Total Assets	$37.37M	$44.27M	$82.37M
YoY Change	-49.37%	-46.26%	24.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.909M	$3.008M	$6.519M
YoY Change	-46.36%	-53.86%	28.94%
Accrued Expenses	$3.457M	$3.300M	$2.528M
YoY Change	23.77%	30.54%	8.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.884M	$6.900M	$5.116M
YoY Change	16.96%	34.87%	0.24%
Total Short-Term Liabilities	$13.25M	$13.23M	$14.16M
YoY Change	-6.04%	-6.57%	13.45%
LONG-TERM LIABILITIES
Long-Term Debt	$28.60M	$30.20M	$37.76M
YoY Change	-19.82%	-20.02%	139.0%
Other Long-Term Liabilities	$11.00K	$29.00K	$0.00
YoY Change	-67.65%		-100.0%
Total Long-Term Liabilities	$28.61M	$30.23M	$37.76M
YoY Change	-19.86%	-19.94%	138.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.25M	$13.23M	$14.16M
Total Long-Term Liabilities	$28.61M	$30.23M	$37.76M
Total Liabilities	$41.86M	$43.48M	$51.92M
YoY Change	-15.95%	-16.25%	83.32%
SHAREHOLDERS EQUITY
Retained Earnings	-$984.8M	-$978.9M	-$944.2M
YoY Change	3.42%	3.67%	6.38%
Common Stock	$980.3M	$979.7M	$976.2M
YoY Change	0.26%	0.36%	5.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00	$0.00	$1.524M
YoY Change	-100.0%	-100.0%	0.0%
Treasury Stock Shares	0.000 shares	0.000 shares	1.223M shares
Shareholders Equity	-$4.496M	$782.0K	$30.45M
YoY Change
Total Liabilities & Shareholders Equity	$37.37M	$44.27M	$82.37M
YoY Change	-49.37%	-46.26%	24.44%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$5.941M	-$7.223M	-$15.46M
YoY Change	-26.0%	-53.27%	-45.47%
Depreciation, Depletion And Amortization	$40.00K	$40.00K	$70.00K
YoY Change	-33.33%	-42.86%	40.0%
Cash From Operating Activities	-$4.940M	-$8.230M	-$16.48M
YoY Change	-34.22%	-50.06%	117.41%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$10.00K	-$20.00K
YoY Change	-100.0%	-50.0%	100.0%
Acquisitions
YoY Change
Other Investing Activities	$4.650M	$4.690M	$4.960M
YoY Change	-283.79%	-5.44%	-75.49%
Cash From Investing Activities	$4.650M	$4.680M	$4.930M
YoY Change	-280.93%	-5.07%	-75.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.640M	-1.360M	34.71M
YoY Change	11.56%	-103.92%	-5698.39%
NET CHANGE
Cash From Operating Activities	-4.940M	-8.230M	-16.48M
Cash From Investing Activities	4.650M	4.680M	4.930M
Cash From Financing Activities	-1.640M	-1.360M	34.71M
Net Change In Cash	-1.930M	-4.910M	23.16M
YoY Change	-83.29%	-121.2%	92.68%
FREE CASH FLOW
Cash From Operating Activities	-$4.940M	-$8.230M	-$16.48M
Capital Expenditures	$0.00	-$10.00K	-$20.00K
Free Cash Flow	-$4.940M	-$8.220M	-$16.46M
YoY Change	-33.87%	-50.06%	117.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	cris	Cash Distribution Paidto Parent Company CashDistributionPaidtoParentCompany	26600000	USD
CY2017Q1	cris	Cash Distribution Paidto Parent Company CashDistributionPaidtoParentCompany	26600000	USD
	cris	Collaboration Agreement Exclusivity Payment CollaborationAgreementExclusivityPayment	10000000	USD
CY2015Q1	cris	Collaborative Arrangement Numberof Optional Additional Terms CollaborativeArrangementNumberofOptionalAdditionalTerms	3	term
CY2015Q1	cris	Collaborative Arrangement Option Fees Numberof Payments CollaborativeArrangementOptionFeesNumberofPayments	2	payment
CY2015Q1	cris	Collaborative Arrangement Option Fees Total CollaborativeArrangementOptionFeesTotal	7500000	USD
CY2015Q1	cris	Collaborative Arrangement Optional Additional Term CollaborativeArrangementOptionalAdditionalTerm	P1Y
	cris	Monthly Retainerfor Advisory Services MonthlyRetainerforAdvisoryServices	35000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	78000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	148000	USD
CY2018Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	227000	USD
CY2018Q3	cris	Treasury Stock Value Acquiredto Date Cost Method TreasuryStockValueAcquiredtoDateCostMethod	1500000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2187000	USD
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	131000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2793000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3300000	USD
	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	plan
CY2018Q3	cris	Treasury Stock Shares Acquiredto Date TreasuryStockSharesAcquiredtoDate	244569	shares
	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33113146	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	CURIS INC
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Trading Symbol TradingSymbol	CRIS
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5423000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3008000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3073000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2855000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	31000	USD
CY2018Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2587000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	977453000	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	979350000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	4439000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1509000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1293000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3980000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	895000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3309000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	135000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	25000	USD
CY2017Q4	us-gaap	Assets Assets	73798000	USD
CY2018Q3	us-gaap	Assets Assets	44265000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	64294000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	34815000	USD
CY2017Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	57512000	USD
CY2018Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	30013000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	21946000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	5272000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	21944000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	5272000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26038000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49837000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38288000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25561000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	23799000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-12727000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	30800000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	45000000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	67500000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33075949	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33113146	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33075949	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33113146	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	331000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	331000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15454000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45285000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7222000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26632000	USD
CY2017Q3	us-gaap	Costs And Expenses CostsAndExpenses	16915000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	49268000	USD
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	9264000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	31858000	USD
CY2018Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	0	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	176000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	139000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.53
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.57
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.80
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4000000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y2M15D
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3409000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10760000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4127000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11741000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	8982000	USD
CY2018Q3	us-gaap	Goodwill Goodwill	8982000	USD
	us-gaap	Interest Expense InterestExpense	2884000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1913000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-218000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-98000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	138000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	1109000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	972000	USD
	us-gaap	Interest Expense InterestExpense	2990000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	193000	USD
CY2018Q3	us-gaap	Interest Payable Current InterestPayableCurrent	173000	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	123000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	331000	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	166000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	541000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	49805000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	43483000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73798000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44265000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14102000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13233000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5900000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5886000	USD
CY2018Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	6925000	USD
CY2018Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	6900000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	35669000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	35700000	USD
CY2018Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	30221000	USD
CY2018Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	30200000	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	21944000	USD
CY2018Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	5272000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	65708000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4322000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1059000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16720000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40850000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25125000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-15457000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-45289000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-7223000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-26634000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-14471000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-42632000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6417000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24185000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	265000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	313000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	34000	USD
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	29000	USD
CY2017Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	104000	USD
CY2018Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-986000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2657000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-806000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2449000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	192000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	44291000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	26145000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	147000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	85000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	989000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1127000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	41809000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	1020000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	112000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	45000000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	43379000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	42950000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	366000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	312000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	3626000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	4434000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	18303000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
CY2017Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	13382000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	38177000	USD
CY2018Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4983000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	19700000	USD
CY2017Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	153000	USD
CY2018Q3	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	153000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-952265000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-978899000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-978900000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2444000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6636000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2847000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7673000	USD
CY2017Q3	us-gaap	Royalty Expense RoyaltyExpense	124000	USD
	us-gaap	Royalty Expense RoyaltyExpense	331000	USD
CY2018Q3	us-gaap	Royalty Expense RoyaltyExpense	154000	USD
	us-gaap	Royalty Expense RoyaltyExpense	417000	USD
CY2018Q3	us-gaap	Severance Costs1 SeveranceCosts1	300000	USD
	us-gaap	Severance Costs1 SeveranceCosts1	300000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3980000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3309000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.64
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.73
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.63
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.66
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.021
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.030
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.020
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.025
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1759429	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.94
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1000000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1386817	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1982596	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.46
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	122000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3206858	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3802637	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.08
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.84
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	8.43
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	88000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3384567	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.14
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.58
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y11M20D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M4D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y4M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2800000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3200000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2018Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	3000000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	23993000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	782000	USD
CY2018Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.2
CY2018Q1	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	1500000	USD
CY2017Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	244569	shares
CY2018Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2018Q1	us-gaap	Treasury Stock Shares Retired TreasuryStockSharesRetired	244569	shares
CY2017Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1524000	USD
CY2018Q3	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29302839	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28824143	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33161592	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33117290	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Nature of Business</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of human cancers. As used throughout these consolidated financial statements, the term “the Company” refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term “Curis” refers to Curis, Inc.</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company conducts its research and development programs both internally and through strategic collaborations. The Company’s clinical stage drug candidates are fimepinostat (CUDC-907), CA-4948 and CA-170: </font></div><div style="line-height:120%;text-align:left;padding-left:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fimepinostat is currently being explored in clinical studies in patients with MYC-altered diffuse large B-cell lymphoma (DLBCL) and solid tumors and has been granted Orphan Drug Designation and Fast Track Designation for the treatment of DLBCL by the U.S. Food and Drug Administration, or FDA in April 2015 and May 2018, respectively. The Company is planning a combination study with venetoclax in DLBCL patients with alterations in both MYC and the BCL2 gene, also referred to as double-hit lymphoma, with planned enrollment commencing in the first half of 2019. The Company expects to have initial clinical data from this combination study in the second half of 2019. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CA-4948 is being tested in a dose escalating clinical trial in patients with non-Hodgkin lymphomas, including those with myeloid differentiation primary response 88, or MYD88, alterations. The Company plans to have initial clinical data from this study in mid-year 2019. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CA-170 is currently undergoing testing in a clinical study in patients with advanced solid tumors and lymphomas. The Company has amended the current study to include mesothelioma patients and the Company plans to begin enrollment of these patients in the first half of 2019 and plans to have initial clinical data from this study with respect to mesothelioma in the second half of 2019. </font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s pipeline also includes CA-327, which is a pre-Investigational New Drug (IND) stage oncology drug candidate. The Company is party to a collaboration with F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under which Roche and Genentech are commercializing Erivedge, a first-in-class orally-administered small molecule Hedgehog signaling pathway inhibitor. Erivedge® (vismodegib) is approved for the treatment of advanced basal cell carcinoma, or BCC.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, and as amended in September 2016, the Company entered into a collaboration, option and license agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited, or Aurigene.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The collaboration with Aurigene is comprised of multiple programs, and Curis has the option to exclusively license each program, including data, intellectual property and compounds associated therewith, once a development candidate is nominated within such program. In October 2015, the Company exercised options to license </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> programs under this collaboration. The first licensed program is in the immuno-oncology field and the Company has named CA-170, an orally-available small molecule antagonist of two immune checkpoints, V-domain Ig suppressor of T cell activation (VISTA) and programmed death ligand-1 (PDL1), as the development candidate from this program. The second licensed program is in the precision oncology field and the Company has named CA-4948, an orally-available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) as the development candidate. In October 2016, the Company exercised its option to license a third program in the collaboration, and designated CA-327, a distinct orally available small molecule antagonist of two immune checkpoints, PDL1 and T-cell immunoglobulin and mucin domain containing protein-3 (TIM3) as the development candidate from this program. In March 2018, the Company exercised its option to license a fourth program, which is an immuno-oncology program. </font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the healthcare industry and would be regulated in the United States by the FDA and in overseas markets by similar regulatory authorities.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company’s business, including, but not limited to: the Company’s ability to advance and expand its research and development programs; the Company’s reliance on Aurigene to successfully discover and preclinically develop drug candidates under the parties’ collaboration agreement; the Company’s reliance on Roche and Genentech to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the Company’s ability to obtain adequate financing to fund its operations; the ability of the Company and its wholly-owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its credit agreement with HealthCare Royalty Partners III, L.P., a Delaware limited partnership managed by HealthCare Royalty Management, LLC, or HealthCare Royalty; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; the Company's dependence on key personnel; the Company’s ability to comply with regulatory requirements; the Company's ability to obtain and maintain applicable regulatory approvals and commercialize any approved product candidates and the Company’s ability to execute on its overall business strategies.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it may receive and make under its current and potential future collaborations. The results of the Company’s operations have varied and will likely continue to vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates; Aurigene’s ability to successfully discover and develop preclinical programs under the Company’s collaboration with Aurigene, as well as the Company’s decision to exclusively license and further develop programs under this collaboration; Roche and Genentech’s ability to successfully commercialize Erivedge; and positive results in Roche and Genentech’s ongoing clinical trials.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has incurred losses and negative cash flows from operations since its inception. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accumulated deficit of approximately </font><font style="font-family:inherit;font-size:10pt;">$978.9 million</font><font style="font-family:inherit;font-size:10pt;">. The Company anticipates that its </font><font style="font-family:inherit;font-size:10pt;">$30.8 million</font><font style="font-family:inherit;font-size:10pt;"> of existing cash, cash equivalents and investments at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> should enable it to maintain its planned operations into the third quarter of 2019. In order to ensure adequate cash resources for 12 months from the issuance date of these financial statements, the Company will reduce or delay spending on its research and development programs, including related clinical trials, and operating expenses to the extent it is unable to raise additional capital through its current at-the-market sale agreement with Cowen and Company, LLC, or Cowen or other potential financing. To the extent that the Company is required to implement reduced or delayed spending plans, the Company expects that such measures would enable the Company to maintain its planned operations into the first quarter of 2020. The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control and it may be unable to raise financing in the next 12 months, or on terms favorable to the Company. The Company’s inability to obtain additional funds in the next 12 months would delay, or cause the Company to reduce in scope or eliminate some of its development programs, potentially delaying the time to market for any of its product candidates, and would have a negative impact on the Company’s financial condition and ability to pursue its business strategies.</font></div></div>

Files In Submission

Name	View Source	Status
0001108205-18-000017-index-headers.html	Edgar Link	pending
0001108205-18-000017-index.html	Edgar Link	pending
0001108205-18-000017.txt	Edgar Link	pending
0001108205-18-000017-xbrl.zip	Edgar Link	pending
cris-20180930.xml	Edgar Link	completed
cris-20180930.xsd	Edgar Link	pending
cris-20180930_cal.xml	Edgar Link	unprocessable
cris-20180930_def.xml	Edgar Link	unprocessable
cris-20180930_lab.xml	Edgar Link	unprocessable
cris-20180930_pre.xml	Edgar Link	unprocessable
cris-9302018x10q3.htm	Edgar Link	pending
cris-9302018x10qexx102.htm	Edgar Link	pending
cris-9302018x10qexx103.htm	Edgar Link	pending
cris-9302018x10qexx311.htm	Edgar Link	pending
cris-9302018x10qexx312.htm	Edgar Link	pending
cris-9302018x10qexx321.htm	Edgar Link	pending
cris-9302018x10qexx322.htm	Edgar Link	pending
curisheadera04.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
updatedpipeline9302018v3a01.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
CURIS INC Stock $cris

2018 Q4 Form 10-Q Financial Statement

#000110820518000017 Filed on November 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS CURIS INC Stock $cris

2018 Q4 Form 10-Q Financial Statement

#000110820518000017 Filed on November 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
CURIS INC Stock $cris